An open-label, multicenter extension study to evaluate the safety and tolerability of natalizumab in subjects with multiple sclerosis who have completed studies C-1801, C-1802, or C-1803

Femme et Homme

| Pays :
| Organes :
| Spécialités :

Extrait

To determine the safety and the immunogenicity of extended treatment with natalizumab when administered at a dose of 300 mg intravenously (IV) to subjects with multiple sclerosis (MS) who have completed studies C-1801, C-1802, or C-1803.

Critère d'inclusion

Male and female subjects with multiple sclerosis who have completed natalizumab studies C-1801, C-1802, or C-1803

Liens

ictrp
euctr